Schering-Plough's new hepatitis C drug positive in Phase II
This article was originally published in Scrip
Executive Summary
Schering-Plough's experimental hepatitis C drug candidate boceprevir improved sustained viral response (SVR) rates when added to standard therapy in treatment-naive patients with chronic hepatitis C genotype 1, interim results of a Phase II study show.